Abstract
1-Methyl-1,4-androstadiene-3,17-dione (SH 489) was characterized as a competitive and irreversible inhibitor of human placental aromatase. The compound and the principal predicted metabolites show no endocrinological side effects suggesting that SH 489 should be suitable as a prototype drug for treatment of estrogen-dependent disease states.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
